search
Back to results

Folic Acid and Zinc Supplementation Trial (FAZST) (FAZST)

Primary Purpose

Pregnancy, Live Birth, Spontaneous Abortion

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
5 mg folic acid and 30 mg elemental zinc
Placebo Comparator: Placebo
Sponsored by
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pregnancy focused on measuring Folic Acid, Zinc, Semen, In vitro fertilization, Assisted reproductive technology, Ovulation induction, Intrauterine insemination, Pregnancy, Live Birth, Abortion, spontaneous

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Couples Inclusion Criteria:

  1. Heterosexual couples in a committed relationship with a female partner aged 18-45 years and male partner aged 18 years and older attempting to conceive and seeking assisted reproduction at participating fertility clinics.
  2. Couples actively trying to conceive.
  3. Couples who are planning ovulation induction (OI), natural fertility optimization methods, or intrauterine insemination (IUI) should be willing to be on the study dietary supplement for at least 3 weeks before starting the next assisted reproduction cycle.Women with regular periods may initiate their fertility therapy at the start of the woman's menstrual cycle following randomization if randomization occurred within the first 10 days of the cycle, but must wait one menstrual cycle if the visit occurred after day 10 of the cycle). For women with irregular periods or amenorrhea, the male must be on the study supplement for 3 weeks prior to initiation of any ovulation induction medication (e.g., clomid, letrozole, gonadotropins).

Couples Exclusion Criteria:

  1. Female partner unwilling to participate (e.g., no abstraction of her assisted fertility treatment record or unwilling to complete baseline visit).
  2. Couples using donor, cryopreserved sperm, or sperm obtained via microsurgical or percutaneous epididymal sperm aspiration.
  3. Couples attempting to conceive with a gestational carrier (surrogate).
  4. Positive urine pregnancy test at screening.

Male Inclusion Criteria:

  1. Willing to provide semen samples according to the proposed schedule at baseline, 2, 4, and 6 months of follow-up.
  2. Able to complete regular study questionnaires and daily journals aimed at capturing ejaculation, sexual intercourse and lifestyle factors considered to affect male fecundity (e.g., cigarette smoking, fever, high temperature environment and other environmental exposures) and other data collection instruments (e.g., physical activity, food frequency questionnaire, stress).

Male Exclusion Criteria:

  1. Age <18 years.
  2. Unwilling to abstain from use of non-study approved dietary supplements or medications containing folic acid or oral preparations containing zinc throughout the study.
  3. Unwilling to abstain from use of testosterone supplementation throughout the study.
  4. Diagnosis of Vitamin B12 deficiency or pernicious anemia.
  5. Consuming a vegan diet.
  6. A known genetic cause of male factor subfertility, including chromosomal disorders related to subfertility (e.g., Y chromosome deletions).
  7. Males currently using and unwilling (or unable) to discontinue the following drugs known to interact with folic acid or interfere with the biosynthesis of folic acid will be excluded.

    1. Dihydrofolate reductase inhibitors: Trimethoprim, Triamterene, Bactrim, Iclaprim
    2. Sulfonamides: Hydrochlorothiazide (HCTZ), Metolazone, Indapamide, Lasix, Bumex, Torsemide, Chlorthalidone, Acetazolamide, Mefruside, Xipamide
    3. Sulfonylureas: Glipizide, Glyburide
    4. Cox-2 inhibitors: Celecoxib
    5. Others: Valproic acid, Probenecid, Sulfasalazine, Sumatriptan, Mafenide, Ethoxzolamide, Sulfiram, Zonisamide, Dorzolamide (optic), Dichlorphenamide, Fluorouracil, Capecitabine, Methotrexate
  8. History of organ transplantation.
  9. Physician diagnosed:

    1. Current poorly controlled chronic diseases such as heart disease, diabetes mellitus, hypertension, cancer, inflammatory diseases, autoimmune, thyroid disease, endocrine dysfunction, liver disease, kidney disease, or HIV/AIDS or other immune-insufficient related illnesses.
    2. Crohn's disease, celiac disease, ulcerative colitis, gastric bypass surgery, lap band surgery or history of intestinal surgery to remove a portion of small bowel. History of diseases/symptoms that require folic acid dietary supplementation, such as megaloblastic anemia, homocystinemia, and homocystinuria.
    3. History of alcohol dependency disorder and/or other drug/substance dependency in the past 180 days.
    4. History of psychoses or other mental conditions that would result in cognitive impairment and inability to participate in any part of this study including the informed consent process, as diagnosed by a physician within the past year.
  10. History of vasectomy without reversal, obstructive azoospermia such as Congenital Bilateral Aplasia of Vas Deferens (CBAVD), or ejaculatory duct obstruction.
  11. Known allergy to folic acid or zinc dietary supplements.

Female Exclusion Criteria:

Age <18 or >45 years.

Sites / Locations

  • Northwestern University
  • University of Iowa
  • Center for Reproductive Medicine
  • University of Utah

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Folic acid and zinc supplementation

Placebo

Arm Description

5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.

Matching placebo, taken orally daily for 6 months.

Outcomes

Primary Outcome Measures

Live Birth
Based on hospital delivery records
Semen Volume
Volume of the ejaculate, mL Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.
Sperm Concentration
Number of spermatozoa per unit of volume of semen Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.
Sperm Motility
% motile (including percentage of progressive motile sperm and percentage of nonprogressive motile sperm) Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.
Sperm Morphology
% normal morphology Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.
DNA Fragmentation Index
Comet assay used to measure sperm DNA integrity based on excess DNA strand breaks Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.
Total Motile Sperm Count
Calculated as semen volume (mL) * sperm concentration (10^6 spermatozoa/mL) * motility (% motile)

Secondary Outcome Measures

Human Chorionic Gonadotropin (hCG) Detected Pregnancy (Implantation)
A quantitative hCG evaluation in serum > 5 milli-international units per milliliter (mIU/ml)
Clinical Intrauterine Pregnancy
Visualized gestational sac in the uterus on ultrasound
Ectopic Pregnancy
Either visualization of no gestational sac in the uterus with a suspicious mass in the adnexa on ultrasound, an hCG level more than 1500 mIU/ml without visualization of an intrauterine gestational sac on ultrasound, or a slowly rising or plateauing serum hCG level without visualization of an intrauterine gestation on ultrasound.
Early Pregnancy Loss
hCG pregnancy loss will be defined as a serum hCG > 5 mIU/ml followed by a decline. Clinically recognized pregnancy losses will be defined as visualization of an intrauterine gestational sac followed by a loss prior to 20 weeks gestation.
Preeclampsia or Gestational Hypertension
Abstracted from hospital records and medical charts
Gestational Diabetes
Abstracted from hospital records and medical charts
Cesarean Delivery
Abstracted from hospital records and medical charts
Preterm Delivery
Abstracted from hospital records and medical charts
Small for Gestational Age
Abstracted from hospital records and medical charts
Gestational Age
Abstracted from hospital records and medical charts
Birth Weight
Abstracted from hospital records and medical charts
Stillbirth
Loss at or after 20 weeks gestation. Determined based on hospital records and medical chart abstraction.
Neonatal Mortality
Abstracted from hospital records and medical charts
Major Neonatal Complications
Abstracted from hospital records and medical charts: includes bronchopulmonary dysplasia, necrotizing enterocolitis, severe intraventricular hemorrhage, periventricular leukomalacia, and retinopathy of prematurity
Structural Malformations
Abstracted from birth record: includes major (n = 21; 6 with known genetic cause), minor (n = 6), and unclassified (n = 2) defects Structural birth defects: includes hydronephrosis/ureteropelvic junction obstruction, transposition of the great arteries, renal agenesis, cleft lip, club feet, multicystic/dysplastic kidney, tetralogy of fallot, gastroschisis, atrioventricular septal defects, other oral-facial defects, other cardiovascular defects, other CNS defects, other eye defects, other oral-facial defects, other anomalies, other syndromes
Severe Maternal Morbidity
Abstracted from delivery record: including postpartum hemorrhage, anemia requiring transfusion, sepsis, seizure, HELLP syndrome or preeclampsia with pulmonary edema
Fertilization Rate Per Cycle, %
Among participants in the IVF stratum Oocytes will be assessed 16-18 hours after insemination or microinjection to determine whether fertilization occurred. Fertilization will be considered normal if two pronuclei and two polar bodies are identified. Oocytes without visible pronuclei will be considered unfertilized. Oocytes with more than two pronuclei will be considered abnormally fertilized, and will thus be discarded.
Number of Good Quality Embryos on Day 5 Per Cycle
Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.
Percentage of Good Quality Embryos on Day 5 Per Cycle
Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.
Number of Embryos Transferred Per Cycle
Among participants in the IVF stratum
Number of Embryos Cryopreserved Per Cycle
Among participants in the IVF stratum
Sperm Penetration Per Cycle, %
Among participants in the IVF stratum
Cells on Day 3 Per Embryo Per Cycle
Among participants in the IVF stratum
Cells on Day 3 Per Embryo Per Cycle, Categorical
Number of cells per embryo among women in the IVF stratum
Cells on Day 5 Per Embryo Per Cycle, Categorical
Among participants in the IVF stratum
Embryo Morphology on Day 3 Per Cycle, Categorical
Among participants in the IVF stratum Embryos will be scored three days after fertilization according to the size and shape of blastomeres and to their degree of fragmentation. Veeck LL. Oocyte assessment and biological performance. Ann N Y Acad Sci 1988;541:259-74.:259-74.
Embryo Morphology on Day 5 Per Cycle, Categorical
Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.
Method of Fertilization Per Cycle
Among participants in the in vitro fertilization (IVF) stratum: method of fertilization classified into intracytoplasmic sperm injection (ICSI) and other
Quality of Embryos Transferred Per Cycle, Categorical
Among participants in the IVF stratum Embryonic grading based on Society for Assisted Reproductive Technologies (SART) morphology criteria
Chromosomal Complement of Embryo Per Cycle
Among participants in the IVF stratum Chromosomal complement in the embryo assessed using methodology cited by Rubio et al. Rubio C, Rodrigo L, Mir P et al. Use of array comparative genomic hybridization (array-CGH) for embryo assessment: clinical results. Fertil Steril 2013 March 15;99(4):1044-8.

Full Information

First Posted
May 13, 2013
Last Updated
November 9, 2020
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT01857310
Brief Title
Folic Acid and Zinc Supplementation Trial (FAZST)
Acronym
FAZST
Official Title
Folic Acid and Zinc Supplementation Trial: A Multi-center, Double-blind, Block-randomized, Placebo-controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
June 2013 (Actual)
Primary Completion Date
June 2019 (Actual)
Study Completion Date
June 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The overarching goal of this trial is to determine if an intervention comprising folic acid and zinc dietary supplementation improves semen quality and indirectly fertility outcomes (i.e., live birth rate) among couples trying to conceive and seeking assisted reproduction. The following study objectives underlie successful attainment of the overarching research goal: To estimate the effect of folic acid and zinc dietary supplementation on semen quality parameters, including but not limited to concentration, motility, morphology, and sperm DNA integrity, relative to the placebo group. To estimate the effect of folic acid and zinc dietary supplementation on fertility treatment outcomes [fertilization, embryo quality, implantation/human Chorionic Gonadotropin (hCG) confirmed pregnancy, clinical pregnancy, live birth], relative to the placebo group. To estimate the association between semen quality parameters, sperm DNA integrity and fertility treatment outcomes (fertilization, embryo quality, clinical pregnancy, live birth) and to identify the best combination of semen quality parameters for prediction of clinical pregnancy and live birth. To estimate the effect of folic acid and zinc dietary supplementation on fertilization rates among couples undergoing assisted reproductive technology procedures, relative to the placebo group. To estimate the effect of folic acid and zinc dietary supplementation on embryonic quality among couples undergoing assisted reproductive technology procedures, relative to the placebo group.
Detailed Description
Two micronutrients fundamental to the process of spermatogenesis, folic acid (folate) and zinc, are of particular interest for fertility as they are of low cost and wide availability. Though the evidence has been inconsistent, small randomized trials and observational studies show that folate and zinc have biologically plausible effects on spermatogenesis and improved semen parameters. These results support the potential benefits of folate on spermatogenesis and suggest that dietary supplementation with folate and zinc may help maintain and improve semen quality, and perhaps, fertility rates. The Epidemiology Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development intends to conduct a multi-site double-blind, randomized controlled clinical trial to evaluate the effect of folic acid and zinc dietary supplementation on semen quality and conception rates among male partners of couples seeking assisted reproduction. Randomization will be stratified (with random sequences of block sizes) by site and assisted reproduction technique (IVF, non-IVF receiving fertility treatment at a study site, and non-IVF receiving fertility treatment at a nonstudy site) to ensure that balance between the treatment groups is maintained within site and within fertility treatment type over the enrollment period. The study is designed with a sample size of 2,400 randomized participants based on obtaining adequate power to detect meaningful differences in the live birth rate between cohorts. Since the comparison of sperm parameters are differences between continuous assay measurements, this sample size will be more than sufficient for the primary sperm parameter comparisons. Additionally, calculations were done to demonstrate adequate statistical power when stratified analysis is to be performed (i.e., sample size distributions among the strata and their corresponding live birth RRs detected at 80% statistical power, with an alpha level of 0.05 and a total sample size of 2400 couples divided among the folic acid/zinc and placebo arms of the trial). Data collection will include screening male and female partners for eligibility, administering baseline questionnaires, and collecting biospecimens in both partners of the couple, body measurements for both partners, daily journal reporting for male partners, medical record abstraction related to required treatment and outcome data, and semen quality of four samples collected at baseline, two, four, and six months following study enrollment. A data coordinating center (DCC) will support the trial. The primary analysis plan is based on an "intention-to-treat" (ITT) approach comparing the two cohorts based on the randomized assignment, both overall and by treatment strata (IVF, non-IVF receiving fertility treatment at a study site, and non-IVF receiving fertility treatment at a nonstudy site).This approach will be applied to the two primary endpoints (semen parameters and live birth rate) as well as designated secondary endpoints (number of follicles, number and proportion of oocytes fertilized). The DCC will perform periodic safety analyses and present interim reports to the Data and Safety Monitoring Board (DSMB) as requested, during the recruitment phases of the trial. It is anticipated that safety analyses will be performed every 6-12 months. The final analysis will be performed upon completion of data collection and editing in the follow-up and close-out phase of the trial. Also one full formal interim analysis is planned and the power calculations with considerations for the choice of optimal time for the analysis have been conducted.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pregnancy, Live Birth, Spontaneous Abortion
Keywords
Folic Acid, Zinc, Semen, In vitro fertilization, Assisted reproductive technology, Ovulation induction, Intrauterine insemination, Pregnancy, Live Birth, Abortion, spontaneous

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
2370 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Folic acid and zinc supplementation
Arm Type
Experimental
Arm Description
5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Matching placebo, taken orally daily for 6 months.
Intervention Type
Dietary Supplement
Intervention Name(s)
5 mg folic acid and 30 mg elemental zinc
Intervention Type
Drug
Intervention Name(s)
Placebo Comparator: Placebo
Primary Outcome Measure Information:
Title
Live Birth
Description
Based on hospital delivery records
Time Frame
At delivery
Title
Semen Volume
Description
Volume of the ejaculate, mL Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.
Time Frame
6 months
Title
Sperm Concentration
Description
Number of spermatozoa per unit of volume of semen Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.
Time Frame
6 months
Title
Sperm Motility
Description
% motile (including percentage of progressive motile sperm and percentage of nonprogressive motile sperm) Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.
Time Frame
6 months
Title
Sperm Morphology
Description
% normal morphology Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.
Time Frame
6 months
Title
DNA Fragmentation Index
Description
Comet assay used to measure sperm DNA integrity based on excess DNA strand breaks Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.
Time Frame
6 months
Title
Total Motile Sperm Count
Description
Calculated as semen volume (mL) * sperm concentration (10^6 spermatozoa/mL) * motility (% motile)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Human Chorionic Gonadotropin (hCG) Detected Pregnancy (Implantation)
Description
A quantitative hCG evaluation in serum > 5 milli-international units per milliliter (mIU/ml)
Time Frame
For IVF, 12 days post embryo transfer for day 5 embryo transfers, and 14 days post embryo transfer for day 3 embryo transfers; for couples undergoing OI/IUI, after self-report of positive pregnancy test
Title
Clinical Intrauterine Pregnancy
Description
Visualized gestational sac in the uterus on ultrasound
Time Frame
approximately 6.5 weeks gestation
Title
Ectopic Pregnancy
Description
Either visualization of no gestational sac in the uterus with a suspicious mass in the adnexa on ultrasound, an hCG level more than 1500 mIU/ml without visualization of an intrauterine gestational sac on ultrasound, or a slowly rising or plateauing serum hCG level without visualization of an intrauterine gestation on ultrasound.
Time Frame
approximately 6.5 weeks gestation
Title
Early Pregnancy Loss
Description
hCG pregnancy loss will be defined as a serum hCG > 5 mIU/ml followed by a decline. Clinically recognized pregnancy losses will be defined as visualization of an intrauterine gestational sac followed by a loss prior to 20 weeks gestation.
Time Frame
hcG-detected pregnancy until 20 weeks of pregnancy
Title
Preeclampsia or Gestational Hypertension
Description
Abstracted from hospital records and medical charts
Time Frame
Delivery
Title
Gestational Diabetes
Description
Abstracted from hospital records and medical charts
Time Frame
Delivery
Title
Cesarean Delivery
Description
Abstracted from hospital records and medical charts
Time Frame
Delivery
Title
Preterm Delivery
Description
Abstracted from hospital records and medical charts
Time Frame
Delivery
Title
Small for Gestational Age
Description
Abstracted from hospital records and medical charts
Time Frame
Delivery
Title
Gestational Age
Description
Abstracted from hospital records and medical charts
Time Frame
Delivery
Title
Birth Weight
Description
Abstracted from hospital records and medical charts
Time Frame
Delivery
Title
Stillbirth
Description
Loss at or after 20 weeks gestation. Determined based on hospital records and medical chart abstraction.
Time Frame
Delivery
Title
Neonatal Mortality
Description
Abstracted from hospital records and medical charts
Time Frame
Delivery
Title
Major Neonatal Complications
Description
Abstracted from hospital records and medical charts: includes bronchopulmonary dysplasia, necrotizing enterocolitis, severe intraventricular hemorrhage, periventricular leukomalacia, and retinopathy of prematurity
Time Frame
Delivery
Title
Structural Malformations
Description
Abstracted from birth record: includes major (n = 21; 6 with known genetic cause), minor (n = 6), and unclassified (n = 2) defects Structural birth defects: includes hydronephrosis/ureteropelvic junction obstruction, transposition of the great arteries, renal agenesis, cleft lip, club feet, multicystic/dysplastic kidney, tetralogy of fallot, gastroschisis, atrioventricular septal defects, other oral-facial defects, other cardiovascular defects, other CNS defects, other eye defects, other oral-facial defects, other anomalies, other syndromes
Time Frame
Delivery
Title
Severe Maternal Morbidity
Description
Abstracted from delivery record: including postpartum hemorrhage, anemia requiring transfusion, sepsis, seizure, HELLP syndrome or preeclampsia with pulmonary edema
Time Frame
Delivery
Title
Fertilization Rate Per Cycle, %
Description
Among participants in the IVF stratum Oocytes will be assessed 16-18 hours after insemination or microinjection to determine whether fertilization occurred. Fertilization will be considered normal if two pronuclei and two polar bodies are identified. Oocytes without visible pronuclei will be considered unfertilized. Oocytes with more than two pronuclei will be considered abnormally fertilized, and will thus be discarded.
Time Frame
Up to 9 months of fertility treatment post-randomization
Title
Number of Good Quality Embryos on Day 5 Per Cycle
Description
Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.
Time Frame
Up to 9 months of fertility treatment post-randomization
Title
Percentage of Good Quality Embryos on Day 5 Per Cycle
Description
Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.
Time Frame
Up to 9 months of fertility treatment post-randomization
Title
Number of Embryos Transferred Per Cycle
Description
Among participants in the IVF stratum
Time Frame
Up to 9 months of fertility treatment post-randomization
Title
Number of Embryos Cryopreserved Per Cycle
Description
Among participants in the IVF stratum
Time Frame
Up to 9 months of fertility treatment post-randomization
Title
Sperm Penetration Per Cycle, %
Description
Among participants in the IVF stratum
Time Frame
Up to 9 months of fertility treatment post-randomization
Title
Cells on Day 3 Per Embryo Per Cycle
Description
Among participants in the IVF stratum
Time Frame
Up to 9 months of fertility treatment post-randomization
Title
Cells on Day 3 Per Embryo Per Cycle, Categorical
Description
Number of cells per embryo among women in the IVF stratum
Time Frame
Up to 9 months of fertility treatment post-randomization
Title
Cells on Day 5 Per Embryo Per Cycle, Categorical
Description
Among participants in the IVF stratum
Time Frame
Up to 9 months of fertility treatment post-randomization
Title
Embryo Morphology on Day 3 Per Cycle, Categorical
Description
Among participants in the IVF stratum Embryos will be scored three days after fertilization according to the size and shape of blastomeres and to their degree of fragmentation. Veeck LL. Oocyte assessment and biological performance. Ann N Y Acad Sci 1988;541:259-74.:259-74.
Time Frame
Up to 9 months of fertility treatment post-randomization
Title
Embryo Morphology on Day 5 Per Cycle, Categorical
Description
Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.
Time Frame
Up to 9 months of fertility treatment post-randomization
Title
Method of Fertilization Per Cycle
Description
Among participants in the in vitro fertilization (IVF) stratum: method of fertilization classified into intracytoplasmic sperm injection (ICSI) and other
Time Frame
Up to 9 months of fertility treatment post-randomization
Title
Quality of Embryos Transferred Per Cycle, Categorical
Description
Among participants in the IVF stratum Embryonic grading based on Society for Assisted Reproductive Technologies (SART) morphology criteria
Time Frame
Up to 9 months of fertility treatment post-randomization
Title
Chromosomal Complement of Embryo Per Cycle
Description
Among participants in the IVF stratum Chromosomal complement in the embryo assessed using methodology cited by Rubio et al. Rubio C, Rodrigo L, Mir P et al. Use of array comparative genomic hybridization (array-CGH) for embryo assessment: clinical results. Fertil Steril 2013 March 15;99(4):1044-8.
Time Frame
Up to 9 months of fertility treatment post-randomization
Other Pre-specified Outcome Measures:
Title
Reproductive Hormones and Other Measured Biomarkers
Description
Urinary, serum, and salivary concentrations of reproductive hormones, particularly androgens, proteomic analysis of human sperm and cardiometabolic risk factors and markers of oxidative stress, as well as measures of trace elements in toenails (collected at month 4 clinic visit). Biospecimens have been collected but laboratory analysis still needs to be done to be able to evaluate these endpoints.
Time Frame
4 or 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Couples Inclusion Criteria: Heterosexual couples in a committed relationship with a female partner aged 18-45 years and male partner aged 18 years and older attempting to conceive and seeking assisted reproduction at participating fertility clinics. Couples actively trying to conceive. Couples who are planning ovulation induction (OI), natural fertility optimization methods, or intrauterine insemination (IUI) should be willing to be on the study dietary supplement for at least 3 weeks before starting the next assisted reproduction cycle.Women with regular periods may initiate their fertility therapy at the start of the woman's menstrual cycle following randomization if randomization occurred within the first 10 days of the cycle, but must wait one menstrual cycle if the visit occurred after day 10 of the cycle). For women with irregular periods or amenorrhea, the male must be on the study supplement for 3 weeks prior to initiation of any ovulation induction medication (e.g., clomid, letrozole, gonadotropins). Couples Exclusion Criteria: Female partner unwilling to participate (e.g., no abstraction of her assisted fertility treatment record or unwilling to complete baseline visit). Couples using donor, cryopreserved sperm, or sperm obtained via microsurgical or percutaneous epididymal sperm aspiration. Couples attempting to conceive with a gestational carrier (surrogate). Positive urine pregnancy test at screening. Male Inclusion Criteria: Willing to provide semen samples according to the proposed schedule at baseline, 2, 4, and 6 months of follow-up. Able to complete regular study questionnaires and daily journals aimed at capturing ejaculation, sexual intercourse and lifestyle factors considered to affect male fecundity (e.g., cigarette smoking, fever, high temperature environment and other environmental exposures) and other data collection instruments (e.g., physical activity, food frequency questionnaire, stress). Male Exclusion Criteria: Age <18 years. Unwilling to abstain from use of non-study approved dietary supplements or medications containing folic acid or oral preparations containing zinc throughout the study. Unwilling to abstain from use of testosterone supplementation throughout the study. Diagnosis of Vitamin B12 deficiency or pernicious anemia. Consuming a vegan diet. A known genetic cause of male factor subfertility, including chromosomal disorders related to subfertility (e.g., Y chromosome deletions). Males currently using and unwilling (or unable) to discontinue the following drugs known to interact with folic acid or interfere with the biosynthesis of folic acid will be excluded. Dihydrofolate reductase inhibitors: Trimethoprim, Triamterene, Bactrim, Iclaprim Sulfonamides: Hydrochlorothiazide (HCTZ), Metolazone, Indapamide, Lasix, Bumex, Torsemide, Chlorthalidone, Acetazolamide, Mefruside, Xipamide Sulfonylureas: Glipizide, Glyburide Cox-2 inhibitors: Celecoxib Others: Valproic acid, Probenecid, Sulfasalazine, Sumatriptan, Mafenide, Ethoxzolamide, Sulfiram, Zonisamide, Dorzolamide (optic), Dichlorphenamide, Fluorouracil, Capecitabine, Methotrexate History of organ transplantation. Physician diagnosed: Current poorly controlled chronic diseases such as heart disease, diabetes mellitus, hypertension, cancer, inflammatory diseases, autoimmune, thyroid disease, endocrine dysfunction, liver disease, kidney disease, or HIV/AIDS or other immune-insufficient related illnesses. Crohn's disease, celiac disease, ulcerative colitis, gastric bypass surgery, lap band surgery or history of intestinal surgery to remove a portion of small bowel. History of diseases/symptoms that require folic acid dietary supplementation, such as megaloblastic anemia, homocystinemia, and homocystinuria. History of alcohol dependency disorder and/or other drug/substance dependency in the past 180 days. History of psychoses or other mental conditions that would result in cognitive impairment and inability to participate in any part of this study including the informed consent process, as diagnosed by a physician within the past year. History of vasectomy without reversal, obstructive azoospermia such as Congenital Bilateral Aplasia of Vas Deferens (CBAVD), or ejaculatory duct obstruction. Known allergy to folic acid or zinc dietary supplements. Female Exclusion Criteria: Age <18 or >45 years.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Enrique F. Schisterman, PhD
Organizational Affiliation
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Sunni L. Mumford, PhD
Organizational Affiliation
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
C. Matthew Peterson, MD
Organizational Affiliation
University of Utah
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jared C. Robins, MD
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ginny L. Ryan, MD, MA
Organizational Affiliation
University of Iowa
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bradley J. Van Voorhis, MD
Organizational Affiliation
University of Iowa
Official's Role
Principal Investigator
Facility Information:
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
University of Iowa
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Facility Name
Center for Reproductive Medicine
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55407
Country
United States
Facility Name
University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84132
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
34656303
Citation
Jenkins T, Aston K, Carrell D, DeVilbiss E, Sjaarda L, Perkins N, Mills JL, Chen Z, Sparks A, Clemons T, Chaney K, Peterson CM, Emery B, Hotaling J, Johnstone E, Schisterman E, Mumford SL. The impact of zinc and folic acid supplementation on sperm DNA methylation: results from the folic acid and zinc supplementation randomized clinical trial (FAZST). Fertil Steril. 2022 Jan;117(1):75-85. doi: 10.1016/j.fertnstert.2021.09.009. Epub 2021 Oct 14.
Results Reference
derived
PubMed Identifier
31910279
Citation
Schisterman EF, Sjaarda LA, Clemons T, Carrell DT, Perkins NJ, Johnstone E, Lamb D, Chaney K, Van Voorhis BJ, Ryan G, Summers K, Hotaling J, Robins J, Mills JL, Mendola P, Chen Z, DeVilbiss EA, Peterson CM, Mumford SL. Effect of Folic Acid and Zinc Supplementation in Men on Semen Quality and Live Birth Among Couples Undergoing Infertility Treatment: A Randomized Clinical Trial. JAMA. 2020 Jan 7;323(1):35-48. doi: 10.1001/jama.2019.18714. Erratum In: JAMA. 2020 Mar 24;323(12):1194.
Results Reference
derived
Links:
URL
https://www.nichd.nih.gov/about/org/diphr/officebranch/eb/folic-acid-zinc
Description
The FAZST trial home page

Learn more about this trial

Folic Acid and Zinc Supplementation Trial (FAZST)

We'll reach out to this number within 24 hrs